Brand Name | Status | Last Update |
---|---|---|
aleve arthritis pain gel | ANDA | 2023-11-30 |
amazon basic care arthritis pain | ANDA | 2024-05-17 |
arthritis pain | ANDA | 2024-12-01 |
arthritis pain reliever | ANDA | 2025-03-04 |
arthritis pain relieving | ANDA | 2023-05-15 |
arthrotec | New Drug Application | 2024-12-02 |
aspercreme arthritis | ANDA | 2025-01-28 |
basic care arthritis pain | ANDA | 2022-01-06 |
berkley and jensen arthritis pain | ANDA | 2023-07-26 |
biorepair sensitive teeth | unapproved drug other | 2017-06-13 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
neuroblastoma | EFO_0000621 | D009447 | — |
hodgkin disease | — | D006689 | C81 |
melanoma | — | D008545 | — |
fibrosarcoma | — | D005354 | — |
rhabdomyosarcoma | — | D012208 | — |
islet cell carcinoma | — | D018273 | C25.4 |
medullary carcinoma | — | D018276 | — |
Code | Description |
---|---|
J9130 | Dacarbazine, 100 mg |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Melanoma | D008545 | — | — | — | 2 | — | — | — | 2 |
Neoplasms | D009369 | — | C80 | — | 1 | — | — | — | 1 |
Sarcoma | D012509 | — | — | — | 1 | — | — | — | 1 |
Leiomyosarcoma | D007890 | — | — | — | 1 | — | — | — | 1 |
Synovial sarcoma | D013584 | — | — | — | 1 | — | — | — | 1 |
Neurofibrosarcoma | D018319 | — | — | — | 1 | — | — | — | 1 |
Nerve sheath neoplasms | D018317 | EFO_0000760 | — | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Sepsis | D018805 | EFO_0001420 | A41.9 | 1 | — | — | — | 3 | 4 |
Toxemia | D014115 | — | — | 1 | — | — | — | 3 | 4 |
Blood coagulation disorders | D001778 | EFO_0009314 | D68.9 | 1 | — | — | — | — | 1 |
Hemostatic disorders | D020141 | — | — | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Disseminated intravascular coagulation | D004211 | — | D65 | — | — | — | — | 3 | 3 |
Venous thromboembolism | D054556 | EFO_0004286 | I74 | — | — | — | — | 1 | 1 |
Thromboembolism | D013923 | — | — | — | — | — | — | 1 | 1 |
Drug common name | Dacarbazine |
INN | dacarbazine |
Description | Dacarbazine is a monocarboxylic acid amide that is 1H-imidazole-4-carboxamide which is substituted at position 5 by a 3,3-dimethyltriaz-1-en-1-yl group. It is used for the treatment of metastatic malignant melanoma, and in combination with other drugs for the treatment of Hodgkin's disease and soft-tissue sarcoma. It has a role as an antineoplastic agent, an alkylating agent, a prodrug and a carcinogenic agent. It is a monocarboxylic acid amide, a member of imidazoles and a triazene derivative. |
Classification | Small molecule |
Drug class | — |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CN(C)/N=N/c1[nH]cnc1C(N)=O |
PDB | — |
CAS-ID | 1185241-28-4 |
RxCUI | — |
ChEMBL ID | CHEMBL476 |
ChEBI ID | — |
PubChem CID | 2942 |
DrugBank | DB00851 |
UNII ID | 7GR28W0FJI (ChemIDplus, GSRS) |